Risks and benefits of optimised medical and revascularisation therapy in elderly patients with angina ? on-treatment analysis of the TIME trial by Kaiser, C
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2004
Risks and benefits of optimised medical and revascularisation therapy in
elderly patients with angina ? on-treatment analysis of the TIME trial
Kaiser, C
Abstract: Aim To assess treatment effects of optimised medical therapy and PCI or CABG surgery on
one-year outcome in patients ￿75 years old with chronic angina
DOI: https://doi.org/10.1016/j.ehj.2004.02.033
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-155558
Journal Article
Published Version
Originally published at:
Kaiser, C (2004). Risks and benefits of optimised medical and revascularisation therapy in elderly patients
with angina ? on-treatment analysis of the TIME trial. European Heart Journal, 25(12):1036-1042.
DOI: https://doi.org/10.1016/j.ehj.2004.02.033
Clinical research
Risks and benefits of optimised medical and
revascularisation therapy in elderly patients with
angina – on-treatment analysis of the TIME trial
Christoph Kaisera, Gabriela M. Kustera, Paul Erneb, Wolfgang Amannc,
Barbara Naegelid, Stefan Osswalda, Peter Busera, Heinz Schl€apfere,
Wolfgang Bretta, Hans-Reinhard Zerkowskia, Christian Schindlerf,
Matthias Pfisterera,*, and the TIME Investigators
a Department of Cardiology, University Hospitals Basel, Petersgraben 4, 4031 Basel, Switzerland
b Kantonsspital, Lucern, Switzerland
c University Hospital, Z€urich, Switzerland
d Triemli Spital, Z€urich, Switzerland
e Kantonsspital, Biel, Switzerland
f Institute of Social and Preventive Medicine, University of Basel, Switzerland
Received 3 December 2003; accepted 4 February 2004
Aim To assess treatment effects of optimised medical therapy and PCI or CABG
surgery on one-year outcome in patients P75 years old with chronic angina.
Methods and Results On-treatment analysis of the TIME data: all re-vascularised
patients (REVASC n ¼ 174: 112 randomised to re-vascularisation and 62 to drugs with
late re-vascularisation) were compared to all patients on continued drug therapy
(MED n ¼ 127: 86 randomised to drugs and 41 to re-vascularisation only). Baseline
characteristics of both groups were similar (age 80 4 years). Risk of death at one
year (adjusted hazard ratio (HR)¼ 1.31; 95%-CI: 0.58–2.99; P ¼ 0:52) and of death/
infarction (adjusted hazard ratio¼ 1.77; 95%-CI 0.91–3.41; P ¼ 0:09) were compa-
rable between REVASC and MED patients. Furthermore, the risk of death within 30
days was even slightly lower among REVASC patients (unadjusted hazard ratio¼ 0.73;
95%-CI: 0.21–2.53; P ¼ 0:98Þ. Overall, REVASC patients had greater improvements in
symptoms and well-being than MED patients ðP < 0:01Þ. Surgical patients had similar
mortality rates as angioplasty patients, but they also had greater symptomatic
improvements ðP < 0:01Þ.
Conclusion Treated medically, elderly patients with chronic angina have a similarly
high 30-day and one-year mortality as patients of the same age being re-vascularised;
however, they can expect lower improvements in symptoms and well being.c 2004 The European Society of Cardiology. Published by Elsevier Ltd. All rights
reserved.
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Introduction
Mortality and complications of coronary artery bypass
grafting (CABG) surgery and percutaneous coronary in-
* Corresponding author. Tel.: þ41-61-265-52-13/14; fax: þ41-61-265-
45-98.
E-mail address: pfisterer@email.ch (M. Pfisterer).
0195-668X/$ - see front matter c 2004 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ehj.2004.02.033
European Heart Journal (2004) 25, 1036–1042
terventions (PCI) are increased in elderly patients with
chronic coronary artery disease (CAD) as compared to
those in younger patients.1–6 However, little is known
about risks and complications of optimised drug therapy in
patients of the same advanced age which may also be
increased. In general, there is a marked lack of data on
the management of elderly patients with chronic CAD
since they have mostly been excluded from randomised
clinical trials.7 Therefore, the risk/benefit ratio of CAD
therapy may differ importantly from that of younger pa-
tients and their number asking for medical advice is in-
creasing rapidly.
The recent Trial of Invasive vs. Medical therapy in
Elderly patients with Chronic Angina (TIME) was the first
prospective randomised treatment trial in elderly pa-
tients with chronic symptomatic CAD.8 It showed that
these patients had a greater benefit from an invasive
strategy as compared to optimised drug therapy re-
garding symptom relief, improvement in quality of life
(QoL) and reduction in major adverse clinical events
(MACE) after 6 months. In this study, patients could be
re-vascularised either by PCI or by CABG surgery. An
early revascularisation hazard was observed, although
the mortality difference between treatment groups was
not significant (8.5% in patients assigned to the inva-
sive, vs. 4.1% in those assigned to the optimised,
medical strategy, P ¼ 0:15). After one year, outcome in
MACE as well as angina severity and measures of QoL
were very similar based on the intention-to-treat anal-
ysis.9 However, since patients were included and
randomised based on their clinical presentation as in
everyday practice and not based on angiographic find-
ings, cross-overs occurred between both strategies. In
fact, 46% of medical treatment assigned TIME patients
had to be re-vascularised during the one-year follow-up
due to medically uncontrolled symptoms, whereas only
73% of all invasive management assigned patients were
actually re-vascularised, making an assessment of the
true effects of medical and revascularisation strategies
difficult. It was therefore the aim of the present pre-
specified “on-treatment” analysis of the TIME data to
more fully describe the effects of optimised medical
therapy and revascularisation on angina severity, mea-
sures of QoL and MACE in patients of the same ad-
vanced age.
Methods
Details of the TIME study have been reported previously.8 In
short, in this prospective multi-centre Swiss trial, patients
aged 75 years or older with chronic angina of at least Cana-
dian Cardiac Society (CCS) class II despite at least two anti-
anginal drugs, were randomised to an optimised medical
therapy or an invasive strategy with coronary angiography
followed by revascularisation (PCI or CABG surgery) if feasible.
The primary end-point was QoL-assessed by standardised
questionnaires and the presence or absence of MACE (all
death, non-fatal myocardial infarction or hospitalisation for
uncontrolled symptoms/acute coronary syndrome with or
without need for revascularisation) after 6 months. Myocardial
infarction was a clinical diagnosis based on chest pain, typical
ECG changes and enzyme elevations apart from the acute in-
tervention. Patients were not included if they had an acute
myocardial infarction within the previous 10 days, concomitant
valvular or other heart disease, pre-dominant congestive heart
failure or gave no consent for a possible revascularisation
procedure. After collection of baseline data, QoL was assessed
by self-administered questionnaires containing the Short Form
36 (SF36),10 the Duke Activity Status Index (DASI)11 and the
Rose angina questionnaire.12 The study was approved by the
Ethics Committee of the Swiss Academy of Medical Sciences
and by the local Ethics Committee of each of the 14 Swiss
centres. Patients gave written informed consent. After both 6
months and one year, all surviving patients were seen again
and underwent the same clinical, symptom and QoL assess-
ments as at baseline.
For this “on-treatment” analysis, all patients with revas-
cularisation attempted during the one-year observation period
(REVASC) were compared to all patients with medical therapy
alone (MED) with regard to symptoms, QoL and MACE up to
one year after randomisation. Thus, for this analysis, hospi-
talisation for medically uncontrolled symptoms leading to re-
vascularisation was not a major event but counted as index
revascularisation and all events in REVASC patients having
occurred before the index revascularisation were disregarded;
accordingly, the day of revascularisation was day one for
these patients. To assess the “treatment hazard” and to put it
into perspective, the 30-day mortality on treatment received
was determined and compared. To analyse the effect of late
revascularisation in patients assigned to medical treatment
on both angina severity and QoL, a special on-treatment
analysis was performed in this subgroup assigned to medical
treatment.
Patient details
The 174 patients in whom revascularisation was attempted
(REVASC) were compared to all 123 patients who received
medical therapy alone (MED) (Fig. 1). The REVASC group con-
sisted of 112 patients assigned to PCI or CABG surgery (109 re-
vascularised early as per protocol and three late after initial
refusal) and 62 patients initially randomised to optimal medical
therapy but who needed revascularisation due to refractory
symptoms during follow-up. Seventy-nine percent of these re-
vascularisations were performed in the first 6 months of the
study. The MED group consisted of 86 patients who were ini-
tially randomised to medical therapy and who stayed on that
therapy and also 41 patients randomised to invasive manage-
ment but in whom revascularisation was not attempted be-
cause they had no significant CAD ðn ¼ 11Þ, revascularisation
did not seem possible ðn ¼ 21Þ or was refused by the patients
ðn ¼ 8Þ; one patient died before revascularisation.
Statistical analysis
For this “on-treatment” analysis, quantitative and score vari-
ables were summarised in terms of mean values and standard
deviations. The comparison between groups was performed by
the Wilcoxon–Mann–Whitney U test. For the comparison of
categorical values between groups, Fisher’s exact test and the
v2 test were used. Changes in quantitative variables within
groups were assessed with the paired t-test, which was also used
to assess changes in score variables within groups. Time-
to-event variables with censored values were described by
Risks and benefits of optimised medical and re-vascularisation therapy in elderly patients 1037
Kaplan–Meier statistics and their inter-group differences were
assessed by the log rank test or by means of proportional hazard
models adjusting for baseline differences in sex, age, CCS-class
and heart rate. The proportional hazard assumption was exam-
ined by including an interaction term between the group indi-
cator variable and time. QoL questionnaires were analysed
according to the specific criteria described previously.5 A priori
differences with a P < 0:05 were considered statistically signif-
icant. However, if statements about all six primary end-points
(i.e., CCS-class, Rose-score, Duke activity score, SF36-general
health, SF36-vitality and number of anti-anginal drugs) were
made, individual P-values were multiplied by 6 (Bonferroni
correction). SAS statistical software version 8.2 (SAS Institute
Inc., Cary, NC, USA) was used for all analyses.
Results
Baseline characteristics and treatments
performed
The baseline characteristics of MED and REVASC patients
were similar (Table 1) with a mean age of 80 years and a
high proportion of women in each group. There were no
significant differences in risk factors, history of CAD,
non-invasively determined left ventricular ejection
fraction or rate of co-morbidities and the same was true
for angina severity and measures of QoL. Eighty percent
of MED patients received at least one additional anti-is-
chaemic drug and in 55% drug dosages were increased. In
the REVASC group, 115 patients (66%) had PCI (86% at
least one stent) and 59 patients (34%) had CABG surgery
(83% at least one arterial conduit). In addition, all pa-
tients were advised regarding lipid lowering and risk
factor modification.
Effect of therapy on symptoms and QoL
The effects of the two anti-anginal treatments on angina
severity and measures of QoL are shown in Fig. 2. With
the exception of vitality, these parameters were signifi-
cantly less improved by MED therapy than by REVASC
therapy, despite the fact that there was also a signifi-
cant treatment effect in this group vs. baseline. In
148 Assigned to Receive Optimal
Medical Strategy
153 Assigned to Receive 
Invasive Strategy
109 Re-
vascularised
44 Received
Medical Treatment*
3 With Late
Re-vascularisation
86 Stayed on
Medical treatment
62 With Late
Re-vascularisation
112 Re-vasularised 41 Stayed on
 MedicalTreatment
174 Re-vascularised
127 Received Medical
Treatment
301 Patients Randomised
Fig. 1 Flow chart of patients for the on-treatment analysis. *Patients assigned to invasive treatment without re-vascularisation at baseline included: no
catheterisation ðn ¼ 7Þ; re-vascularisation not feasible ðn ¼ 19Þ; re-vascularisation refused ðn ¼ 7Þ; no significant CAD ðn ¼ 11Þ. Note that 62/148 pa-
tients assigned to medical treatment and 3/44 patients assigned to invasive treatment without re-vascularisation at baseline were re-vascularised during
follow-up for refractory symptoms.
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accordance with these findings, MED patients needed
more anti-anginal drugs after one year than REVASC pa-
tients (2.4 0.11 vs. 1.4 0.08; P < 0:00001).
Effect of therapy on MACE
Observed one-year mortality risks were comparable be-
tween REVASC and MED patients (adjusted HR¼ 1.31;
95%-CI: 0.58–2.99; P ¼ 0:52). The observed cardiac
mortality risk was the same in both groups (adjusted
hazard ratio¼ 1.02; 95%-CI: 0.41–2.51; P ¼ 0:98). In
addition, the 30-day mortality index of “treatment haz-
ard” was not significantly different between the two
treatment groups (HR¼ 0.73; 95%-CI: 0.21–2.53;
P ¼ 0:62). Observed risks of MACE were very similar be-
tween the two groups (adjusted HR¼ 1.10; 95%-CI:
0.69–1.76; P ¼ 0:69). Only the observed risk of death
and/or myocardial infarction showed a larger difference
between REVASC and MED patients (adjusted HR¼ 1.77;
95%-CI: 0.91–3.41; P ¼ 0:09). The survival curves of MED
and REVASC patients are illustrated in Fig. 3 and showed
no relevant differences over the one-year observation
period (see Table 2).
Comparison between patients re-vascularised by
PCI and by CABG surgery
The choice of revascularisation mode, PCI or CABG sur-
gery, was left to the discretion of local investigators/
operators and therefore was done based on an assess-
ment of “suitable anatomy” vs. “expected interventional
risk”. Accordingly, the 34% of patients treated by CABG
surgery differed significantly from the 66% treated by PCI
(Table 3); patients with PCI had less multi-vessel disease
whereas left ventricular ejection was not significantly
different from that of patients with CABG surgery. Pa-
tients selected for PCI had a similar 30-day and one-year
mortality rate as patients with CABG surgery: 30 day
early mortality: HR¼ 0.76 (95%-CI: 0.13–4.56; P ¼ 0:77);
mortality up to 12 month follow-up: adjusted HR¼ 0.97
(95%-CI: 0.31–3.05; P ¼ 0:96) and there was no signifi-
cant difference in the risk of death or myocardial in-
farction after PCI as compared to CABG surgery (adjusted
HR¼ 1.42; 95%-CI: 0.58–3.49; P ¼ 0:44). We noted a
surprisingly low repeat target vessel revascularisation
CCS ROSE * Anti-anginal drugs 
P<0.0003 P=0.005 P<0.0001 -2.5
-2
-1.5
-1
-0.5
0
General Health †
(SF 36) 
Vitality †
(SF36) 
Duke Activity
Status Index ††
0
2
4
6
8
10
12
P=0.002 P=0.02 P=0.003 
Fig. 2 Mean change (1 SD) from baseline in angina severity, measures in
QoL and anti-anginal drug use over time in both treatment groups (MEDI-
CAL: grey bars, REVASC: black bars; P-values relate to differences in
groups). ROSE Score, Canadian Cardiac Society (CCS) class 4 indicates pain
at rest and 0 indicates no pain. ySF 36 score from 0 to 100, with higher score
indicating a more favourable status. z Score on a scale from 0 to 58, with
higher scores indicating a more favourable status. Note. CCS class, ROSE
Score and anti-anginal drug use were not normally distributed basd on the
inclusion criteria for this study; therefore P-valuesmay be over-estimated.
Table 1 Baseline characteristics
MED ðn ¼ 127Þ REVASC ðn ¼ 174Þ P
Age (years) 80.3 3.7 79.6 3.5 0.09
Women (%) 48 40 0.18
History of AMI (%) 44 49 0.41
History of PCI/CABG (%) 18 16 0.63
P2 risk factors (%) 54 58 0.52
P2 co-morbidities (%) 32 23 0.11
Angina CCS class 3.0 0.9 3.1 0.8 0.13
Anti-anginal drugs (n; mean SD) 2.5 0.6 2.5 0.7 0.92
LVEF (%; mean SD) 52.6 11.8 52.6 13.0 0.99
General Health (SF 36)a 56.4 16.9 52.5 18.3 0.06
Vitality (SF 36)a 48.5 20.9 44.7 21.6 0.14
Duke Activity Status Indexb 13.6 11.2 12.2 11.4 0.20
AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; CCS, Canadian Cardiac Society; LVEF, left ventricular ejection fraction;
PCI, percutaneous coronary intervention.
aSF 36 score from 0 to 100: higher scores indicating a more favourable status.
bScore on a scale from 0 to 58: higher scores indicating a more favourable status.
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rate in PCI patients of only 8%. However, angina severity
showed a significantly stronger decrease, and the vitality
score a significantly stronger increase, after CABG sur-
gery than after PCI.
Comparison according to completeness of
revascularisation
We analysed whether the major epicardial vessels were
effectively re-vascularised (open artery without P75%
obstruction after successful PCI or a successfully grafted
artery) in order to assess whether completeness of re-
vascularisation was responsible for the difference in
symptomatic and QoL status. By this definition, complete
revascularisation was achieved in 42% of patients with
PCI (48/115) and in 68% of patients with CABG surgery
(40/59; P < 0:01). Patients with incomplete revasculari-
sation showed a similar 30-day and one-year mortality
rate as patients with complete revascularisation: 30-day
early mortality: HR¼ 0.69 (95%-CI: 0.11–4.11; P ¼ 0:68);
mortality up to 12-month follow-up: adjusted HR¼ 0.99
(95%-CI : 0.34–2.87; P ¼ 0:99). In addition, the risk of
deaths or myocardial infarctions after revascularisation
was not significantly higher among patients with incom-
plete revascularisation than among those with com-
plete revascularisation (HR¼ 1.74; 95%-CI : 0.78–3.86;
P ¼ 0:18). As expected patients with full revascularisa-
tion had a markedly higher decrease in anti-anginal drugs
after one year ðP ¼ 0:04Þ. However, there were no sig-
nificant differences in angina severity and QoL between
completely and incompletely re-vascularised patients
after one year.
On-treatment findings in medical
strategy-assigned TIME patients
The intention-to-treat analysis of the TIME data showed
an early intervention hazard with the invasive strategy8
and a late benefit in symptom relief/improvement in
Table 3 PCI vs. CABG: baseline characteristics
PCI ðn ¼ 115Þ CABG ðn ¼ 59Þ P
Age (years) 79.6 3.6 79.4 3.4 0.72
Women (%) 38 44 0.46
History of AMI (%) 50 47 0.79
Hypertension (%) 56 76 0.008
History of PCI/CABG (%) 21 5 0.007
P 2 risk factors (%) 57 59 0.81
P 2 co-morbidities (%) 23 22 0.83
Multi-vessel disease (%) 81 98 0.0007
Complete re-vascularisation (%) 42 68 0.0013
Anti-anginal drugs (n; mean SD) 2.5 0.7 2.5 0.7 0.58
LVEF (%; mean SD) 51.6 13.4 55.4 11.4 0.24
Abbreviations as in Table 1.
Table 2 Effects of therapy on MACE/mortality hazard ratios (and 95%-CI) for different risks between re-vascularised patients
(REVASC, n ¼ 174) and medically treated patients (MED, n ¼ 127)
Hazard ratio REVASC vs.
MED (unadjusted)
P-valuea Hazard ratio REVASC vs.
MED (adjustedb)
P-valueb
Death 1.11 (0.51–2.43) 0.79 1.31 (0.58–2.99) 0.52
Cardiac death 0.85 (0.36–2.02) 0.72 1.02 (0.41–2.51) 0.98
Death up to 30 days 0.73 (0.21–2.53) 0.62 –c
Death and/or MI 1.57 (0.84–2.95) 0.15 1.77 (0.91–3.41) 0.09
MACE 0.94 (0.6–1.47) 0.78 1.10 (0.69–1.76) 0.69
MACE, major adverse cardiac events; MI, myocardial Infarction.
a From log rank test.
b From multiple Cox regression model controlling for sex, age, CCS-class and heart rate at rest.
c Event numbers were too small for a multiple model.
Long Rank p=0.79 
Pr
op
or
tio
n 
of
 s
ur
viv
or
s 
Days since intervention 
Fig. 3 Time-to-death for both treatment groups. Solid line: optimal
medical treatment, dotted line: re-vascularised patients.
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QoL with the optimised medical strategy, such that
after one year no significant differences in outcome
between the two groups remained.9 In this regard, the
on-treatment analysis provided important insights. The
relatively high 6-month mortality rate of 8.5% in pa-
tients assigned to invasive treatment (compared to 4.1%
in patients assigned to medical treatment, P ¼ 0:15)
was actually 7.3% in 109 invasive patients receiving and
11.4% in 44 invasive patients not receiving, revascular-
isation as per protocol. Since all 11 invasive patients
without significant CAD survived, the 6-month mortality
of 33 non-re-vascularised invasive patients with CAD
was 15.2% – double that of re-vascularised patients
ðP ¼ 0:18Þ. The late symptomatic and QoL benefit of
patients assigned to medical treatment was exclusively
found in patients with late revascularisation, whereas
patients assigned to continual medical treatment re-
mained more symptomatic with a lower level of well-
being despite more drugs.
Discussion
In this prospective on-treatment analysis of the first
randomised trial comparing an invasive, with an optimal
medical, strategy in elderly patients with chronic symp-
tomatic CAD, MED treated patients had a similarly high
one-year mortality rate as REVASC patients of the same
advanced age. This indicates that, compared to younger
patients with CAD as usually studied, mortality is in-
creased in these elderly CAD patients whatever treat-
ment they received. In fact, the early intervention
hazard observed previously8 was due to the high mor-
tality of patients assigned to invasive treatment not
being re-vascularised rather than because of the inter-
vention. REVASC therapy induced a greater relief from
angina and a greater improvement in measures of QoL, a
finding which also explains the late benefit observed in
patients assigned to medical treatment with intention-
to-treat.9 Patients selected for PCI had a similar inter-
vention mortality and a similar one-year death/non-fatal
myocardial infarction rate to patients undergoing CABG
surgery. However, CABG gave greater symptomatic relief
and improvement in QoL after one year and was also
associated with a higher rate of complete revasculari-
sation. Obviously the choice of the revascularisation
mode by operators led to a reasonable clinical outcome,
since the overall effect of REVASC therapy regarding
symptom relief and QoL assessment was significantly
better than after MED therapy.
Comparison of revascularisation vs. medical
therapy
In younger patients, the randomised CABG surgery,
compared with medical therapy, studies have shown a
survival advantage of surgery in high risk patient
groups.13–15 These studies also showed an improvement
in symptomatic status and QoL, as noted in the TIME
study for elderly patients. The Angioplasty Compared to
Medical Therapy (ACME),16 the Randomised Intervention
Treatment of Angina 2 (RITA-2),17 and the Atorvastatin
Versus Revascularisation Treatment (AVERT)18 studies
were the only true prospective comparisons between
PCI and medical therapy, related to younger patients
with single or double vessel disease. They demon-
strated an improvement in the severity of angina after
PCI, although this was at the cost of an excess mor-
tality and myocardial infarction rate in RITA-2.19 The
TIME study extended these findings for the first time to
an elderly patient population and, importantly, dem-
onstrated an increased risk also in elderly CAD patients
on optimised drug therapy in the present on-treatment
analysis. A recently published retrospective analysis of
>6000 elderly patients indirectly supported these find-
ings by showing that elderly patients have greater ab-
solute risk reductions associated with surgical or
percutaneous revascularisations than younger patients
do.20
Comparison of PCI with CABG surgery
A meta-analysis of studies comparing PCI to CABG sur-
gery21 showed a similar long-term mortality and re-in-
farction rate for both procedures but more repeated
interventions and a poorer outcome regarding angina
relief after PCI. Our findings in elderly patients are in
accordance with these results. Restenosis was the main
cause for the higher rate of repeat interventions; this
may soon be minimised if the first results of drug-coated
stents22 are further substantiated. As noted in the pres-
ent analysis, completeness of revascularisation could not
fully explain this difference in unselected elderly multi-
vessel disease patients either, partly because surgeons
achieved full revascularisation in only two-third of these
patients. In younger patients it has been shown that
complete revascularisation by angioplasty can improve
outcome.23
Limitations of this study
The present pre-defined “on-treatment” analysis of a
prospective randomised trial has its immanent limita-
tions as to patient selection. Thus, the potential for bias
is substantial because both treatment groups contain
failures of the other treatment, i.e., failure of medical
treatment among REVASC or the impossibility, or lack of
necessity, to perform revascularisation among MED pa-
tients. In addition, the patient number is relatively low.
This study, however, complements the primary inten-
tion-to-treat analysis and provides important clues for its
interpretation and gives the first prospective trial data in
elderly patients with chronic CAD. Finally, the optimised
medical therapy was that which could be maximally
achieved and tolerated by patients of this age group,
which was less than what maximal lipid lowering and risk
factor management could be; however. However, there
is almost no direct evidence of their effectiveness in 80-
year-old patients.
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Conclusions
This prospective “on-treatment” analysis of the TIME
patient population provides important insights into the
effects of optimised medical and revascularisation
therapy in these 80-year-old patients. The mortality of
MED patients was similar to that of REVASC patients of
the same advanced age, indicating that mortality is in-
creased in these elderly CAD patients whatever treat-
ment they receive. The early mortality hazard of invasive
management was mainly due to the high mortality of CAD
patients assigned to invasive management who could not
be re-vascularised, rather than to the PCI or CABG sur-
gery itself. Overall, revascularisation led to a significant
improvement in angina severity and measures of QoL,
compared to the optimised medical therapy. This finding
could also explain the overall late benefit observed in
patients assigned to medical treatment by intention-to-
treat. Patients selected for PCI based on a “suitable”
coronary anatomy had a similar early and one-year
death/mortality rate as patients who underwent CABG
surgery; however, their benefit in QoL and angina re-
lief may be smaller. Therefore, elderly patients with
chronic angina should be offered invasive evaluation and
revascularisation, if feasible, because mortality is in-
creased similarly with both treatments but improve-
ments in symptoms and QoL are greater after successful
revascularisation.
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